<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="487">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05154812</url>
  </required_header>
  <id_info>
    <org_study_id>BJDH-YZY</org_study_id>
    <nct_id>NCT05154812</nct_id>
  </id_info>
  <brief_title>Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter Ratio</brief_title>
  <official_title>Based on the Comprehensive Evaluation System of Platelet Count/Splenic Length-diameter Ratio to Explore the Efficacy of Yang Yin Fu Zheng Jie Du Therapy in Delaying the Progression of HBV Associated Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Ditan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical research of Yang Yin Fu Zheng Jie Du therapy in HBV associated Hepatocellular&#xD;
      Carcinoma based on the platelet count/splenic length-diameter ratio.The purpose of this study&#xD;
      is to establish the efficacy evaluation system combined with platelet/splenic length-diameter&#xD;
      ratio, and to clarify the effect of this method on relieving hepatitis B cirrhosis and&#xD;
      delaying the progression of Hepatocellular Carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor progression rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to tumor progression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the platelet count/splenic length-diameter ratio</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (QOL) questionnaire</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Yang Yin Fu Zheng Jie Du therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine medical care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yang Yin Fu Zheng Jie Du therapy</intervention_name>
    <description>Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.</description>
    <arm_group_label>Yang Yin Fu Zheng Jie Du therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Routine medical care</intervention_name>
    <description>Routine medical care</description>
    <arm_group_label>Routine medical care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Meet the criteria of hepatocellular carcinoma Patients who tested positive for hepatitis B&#xD;
        surface antigen (HBsAg) for &gt;6 months Liver function grade child-Pugh A/B Patients who have&#xD;
        agreed to select local treatment according to the Guidelines for the Diagnosis and&#xD;
        Treatment of Primary Liver Cancer (2017) TCM syndrome differentiation belongs to deficiency&#xD;
        of qi and Yin, stasis and toxin accumulation syndrom Informed consent from the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient with other hepatitis virus infections or alcoholic liver, autoimmunity liver,&#xD;
        primary biliary cirrhosis, genetic metabolic liver disease, and previous liver&#xD;
        transplantation; Serious problem of heart, lung, brain, blood and other important organs;&#xD;
        Patients with metastatic liver cancer; Pregnant or child breast feeding women; Mental or&#xD;
        cognitive disorders; Who are allergic to the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhiyun Yang, doctor</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>Beijing</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 8, 2021</study_first_submitted>
  <study_first_submitted_qc>December 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>December 8, 2021</last_update_submitted>
  <last_update_submitted_qc>December 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Ditan Hospital</investigator_affiliation>
    <investigator_full_name>Zhiyun Yang</investigator_full_name>
    <investigator_title>Archiater, Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

